Atai Life Sciences N.V. (ATAI)

NASDAQ: ATAI · Real-Time Price · USD
1.115
-0.045 (-3.88%)
Oct 7, 2024, 3:42 PM EDT - Market closed
-3.88%
Market Cap 187.10M
Revenue (ttm) 378,000
Net Income (ttm) -58.07M
Shares Out 167.80M
EPS (ttm) -0.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 326,348
Open 1.160
Previous Close 1.160
Day's Range 1.105 - 1.200
52-Week Range 1.025 - 2.850
Beta 0.78
Analysts Strong Buy
Price Target 10.50 (+841.7%)
Earnings Date Nov 12, 2024

About ATAI

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 18, 2021
Employees 83
Stock Exchange NASDAQ
Ticker Symbol ATAI
Full Company Profile

Financial Performance

In 2023, Atai Life Sciences's revenue was $314,000, an increase of 34.76% compared to the previous year's $233,000. Losses were -$40.22 million, -73.60% less than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ATAI stock is "Strong Buy." The 12-month stock price forecast is $10.5, which is an increase of 841.70% from the latest price.

Price Target
$10.5
(841.70% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG

MONTRÉAL, Oct. 02, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”), a leading drug delivery company focused on the development and manufacturing of pharmaceutical ...

5 days ago - GlobeNewsWire

atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...

4 weeks ago - GlobeNewsWire

Psychedelic Stock Deep Dive: Atai Life Sciences

After the FDA's rejection of Lykos Therapeutics' NDA for MDMA therapy, we take a more complete look at major psychedelic stocks. Atai Life Sciences is an early mover with a unique company structure an...

4 weeks ago - Seeking Alpha

atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

• Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to initiate a Phase 2 study in treatment-resistant depression patients around YE'24  • Announced clinical development plans for...

7 weeks ago - GlobeNewsWire

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stre...

Other symbols: CMPSCYBNMNMD
2 months ago - Market Watch

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

NEW YORK and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences  (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...

2 months ago - GlobeNewsWire

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental h...

3 months ago - GlobeNewsWire

atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

NEW YORK and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental h...

3 months ago - GlobeNewsWire

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental he...

4 months ago - GlobeNewsWire

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

NEW YORK and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental he...

5 months ago - GlobeNewsWire

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

NEW YORK and BERLIN, April 24, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...

5 months ago - GlobeNewsWire

atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

NEW YORK and BERLIN, April 17, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...

6 months ago - GlobeNewsWire

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

NEW YORK and BERLIN, March 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences  (NASDAQ: ATAI) (“atai” or “Company”) a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...

6 months ago - GlobeNewsWire

atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

- A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect  in TRD patients, with 45% of patients in clinical remission at week 12

6 months ago - GlobeNewsWire

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

NEW YORK and BERLIN, March 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...

7 months ago - GlobeNewsWire

atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference

NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorde...

7 months ago - GlobeNewsWire

atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) today announced that Anne Johnson, the Company's interim Chief Financial Officer since Oc...

8 months ago - GlobeNewsWire

atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

NEW YORK and BERLIN, Jan. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental h...

9 months ago - GlobeNewsWire

Atai Life Sciences: A Promising Venture In The Psychedelic Therapy Market Trading Below Cash Value

ATAI Life Sciences is a biopharmaceutical company focused on developing psychedelic-based treatments for mental health conditions. The company has a diverse portfolio of drug candidates in various cli...

11 months ago - Seeking Alpha

atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights

NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorde...

11 months ago - GlobeNewsWire

atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorde...

1 year ago - GlobeNewsWire

atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants

NEW YORK and BERLIN, Oct. 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorde...

1 year ago - GlobeNewsWire

atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK and BERLIN, Sept. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disord...

1 year ago - GlobeNewsWire

atai Life Sciences to Participate in Upcoming September Investor Conferences

NEW YORK and BERLIN, Sept. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disord...

1 year ago - GlobeNewsWire

Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved Therapies

Atai Life Sciences is advancing RL-007 for the treatment of cognitive impairment associated with schizophrenia, with top-line results expected in the 2nd half of 2024. The company is also working on a...

1 year ago - Seeking Alpha